Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Scancell Holdings ( (GB:SCLP) ) has issued an announcement.
Scancell Holdings plc has announced the issuance of share options to its executive directors as part of the company’s long-term incentive plan. The options, granted to CEO Phil L’Huillier, CSO Lindy Durrant, and CFO Sath Nirmalananthan, are intended to incentivize and retain key personnel. The options, which have an exercise price of 11.7 pence each, will vest over three years and represent a significant portion of the company’s issued share capital. This strategic move aims to align the interests of the executive team with those of shareholders and fortify Scancell’s positioning in the competitive biopharmaceutical industry.
More about Scancell Holdings
Scancell Holdings plc is a clinical-stage biopharmaceutical company specializing in the development of novel immunotherapies for cancer. The company leverages its proprietary research on the human adaptive immune system to create innovative treatments targeting significant unmet needs in cancer. Scancell’s product pipeline is built on four technology platforms: Moditope® and ImmunoBody® for vaccines, and GlyMab® and AvidiMab® for antibodies. These platforms aim to induce immune responses or redirect immune cells to target and destroy cancer cells through vaccines or monoclonal antibodies.
YTD Price Performance: -19.53%
Average Trading Volume: 1,082,760
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £92.27M
Learn more about SCLP stock on TipRanks’ Stock Analysis page.
